A Phase 2, Adaptive, Double-blinded, Placebo Controlled, Randomized, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of Intracoronary Infusion of NAN-101 in Adult Subjects With New York Heart Association (NYHA) Class III Heart Failure and Non-ischemic Cardiomyopathy
- Disease/Condition
- Congestive Heart Failure
- Drug/Device/Intervention
- NAN-101
- Study type
- Interventional
- Intervention type
- drug
- Primary sponsor
- Asklepios Biopharmaceutical, Inc.
- Phase
- Phase 2
- Start date
- Dec 01, 2022
- End date
- Dec 01, 2029
- Enrollment
- 150 participants
Cardiovascular Related Death,NYHA Classification,Left Ventricular Ejection Fraction,Peak Oxygen Update (VO2),Six Minute Walk Test
This is a Phase 2 adaptive, double-blinded, placebo-controlled, randomized, multi-center
 trial study to evaluate the safety and efficacy of a single dose of NAN-101, administered via
 antegrade intracoronary artery infusion, in males and females age 18 years with non-ischemic
 cardiomyopathy and NYHA Class III symptoms of HF.
 
 Subjects will be randomized into one of three treatment groups in a 1:1:1
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05598333
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT05598333 through Pure Global AI's free database. This Phase 2 trial is sponsored by Asklepios Biopharmaceutical, Inc. and is currently Not yet recruiting. The study focuses on Congestive Heart Failure. Target enrollment is 150 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.